Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon May 09, 2022 11:37am
184 Views
Post# 34667083

RE:The Spin...

RE:The Spin...Some back-up for the below post.

Available on sedar:

The PSUs were granted to certain key executives to incentivize and reward management upon the achievement of FDA approval for PMX and FDA approval for in-home use of DIMI. These maximum number of PSUs are conditional, and will only vest upon achievement of FDA approvals achieved upon specific target timelines.



mercedesman wrote: ...is in full vigor...as usual.

How is everyone's equity portfolios working out lately?


Since November 2021:
  • Nasdaq down about 25% +
  • Cryoto's down about 50%
  • TSX down about 10 % (saved by oils)


Meanwhile, the lowly Spectralor up about 50% off November lows (when you should have been buying - I know I was).  Hating the delays and absoltue performance vs true underlying value, BUT LOVING this relative performance.


Anyway, despite the recent market carnage, it's looking like a good place to hide (up 5% today while the general markets are down big again e.g DOW - 500 pts +) .  For once, being completely off the radar (some would say - by design), is an apparent advantage.   Silently awaiting the inevitable endgame, with at least two ways to win (PMX & Dialco) - as it move inexorably* towards a conclusion


Should be 40 - 45 patients by end of May (with any luck).  About halfway to Interim Data Release and another $ x,xxx,xxx  from Baxter the $ 37 B MC partner.

I wonder if the DIMI Trial partner will put up any cash to get first dibs on only the thrid competitor into a $ 13B market (with "game-channging" technology and the ability to address/break down barriers to adoption?  Let's see if Seto can prove to all shareholders, why the BoD has so much confidence in him.  I kinda like that he doesn't score big, unless and until certain milestones are achieved.

MM


*in·ex·o·ra·bly
/ineks()rbl/
 
adverb
  1. in a way that is impossible to stop or prevent.
    "the conflict was to lead inexorably to the outbreak of World War III"



<< Previous
Bullboard Posts
Next >>